REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

16/04/2019 17:15

RNS Number : 4038W
GlaxoSmithKline PLC
16 April 2019
 


GlaxoSmithKline plc (the 'Company')
Transaction notification




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E N Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
   




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


1856.065




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R G Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


835.687




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP, Human Resources




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


9.069




 
 




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr S P Dingemans




b)


Position/status


Executive Director




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


0.001




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


SVP & General Counsel




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053
 




b)


Nature of the transaction


Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




$ 40.8259


0.002




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


SVP & General Counsel




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


0.000034




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 




b)


Nature of the transaction


Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019




c)


Price(s) and volume(s)






Price(s)


Volume(s)




$ 40.8259


22.812




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 


 
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


839.365




  
 




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Jackson




b)


Position/status


 PCA of Ms S Jackson (SVP, Global Communications and CEO Office)




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


73.793




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 


 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mrs S Jackson




b)


Position/status


 SVP, Global Communications and CEO Office




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


112.492




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 


 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 




b)


Nature of the transaction


Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 April 2019




c)


Price(s) and volume(s)






Price(s)


Volume(s)




$ 40.8259


947.143




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


3072.811




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharma Supply Chain




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


590.721




  
 




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P C Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


706.619




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 


 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mrs K Thomson




b)


Position/status


 PCA of Mr P C Thomson (President, Global Affairs)




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.5009


154.042




 
  




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 
 
 
 




e)


Date of the transaction


2019-04-15




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQQLFFKZFFBBX